Table 4

Outcome measures at baseline and follow-up points, mean and (SD)

OutcomeBaselineHalfway*14 weeks
PAM69.7 (17.8)65.8 (14.8)68.1 (10.3)
FMA-UE†37.7 (17.2)39.0 (20.1)36.4 (22.4)
MAL‡2.00 (1.4) | 2.26 (1.5)2.94 (1.2) | 3.09 (1.2)3.24 (1.3) | 3.17 (1.2)
mRS2.8 (1.1)2.5 (0.8)1.9 (0.9)
VAS (pain)0.8 (1.0)2.5 (1.9)2.8 (2.3)
MoCA§22.6 (6.9)24.0 (5.1)25.3 (1.0)
MoCA¶17.8 (3.4)19.0 (1.9)18.3 (2.4)
AT0.2 (0.4)0.1 (0.3)0.1 (0.3)
EQ-5D-5L index0.462 (0.3)0.585 (0.1)0.606 (0.2)
EQ-5D-5L VAS57.3 (20.7)72.7 (9.8)74.2 (15.1)
SUS84.6 (13.1)
  • * Performed at week 8 for phase 1 participants; week 7 for phase 2.

  • †Only performed during phase 1. Participants who started in phase 1 but finished their participation after lock down, did not complete this measure subsequently.

  • ‡How much score | How well score

  • §Full version applied before lockdown measures (scores out of 30).

  • ¶Telephone version applied after lockdown measures (scores out of 22).

  • AT, Albert’s Test; EQ-5D-5L, EuroQol-5 Dimensions-5 Level; FMA-UE, FuglMeyer Upper Extremity; MAL, Motor Activity Log; MoCA, Montreal Cognitive Assessment; mRS, Modified Rankin Scale; PAM, Patient Activation Measure; SUS, System Usability Scale; VAS, Visual Analogue Scale (pain).